Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies.

Trial Profile

Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Pegaspargase (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Hodgkin's disease; Leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jul 2017 Status changed from completed to discontinued due to funding issues.
    • 30 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top